Table 1 Clinical study demographics, sample collection, and treatment outcomes
Parameter | PKPD group (primary analysis) | PD group (external validation) | Total |
|---|---|---|---|
Total no. of children | 179 | 562 | 741 |
Total no. of samples (capillary/venous plasma) | 466/71 | NA | NA |
Total monthly dose of piperaquine base (mg kg−1) | 29.2 (18.0–39.0) | 29.7 (16.7–55.4) | 29.7 (16.7–55.4) |
Total monthly dose of dihydroartemisinin (mg kg−1) | 6.32 (3.90–8.45) | 6.43 (3.61–12.0) | 6.43 (3.61–12.0) |
Continuous and categorical covariates at admission | |||
Age (months) | 32.1 (2.33–58.1) | 24.0 (3.00–59.3) | 26.1 (2.33–59.3) |
Body weight (kg) | 11.0 (4.20–18.3) | 10.5 (5.00–21.0) | 10.6 (4.20–21.0) |
Axillary temperature at admission (ºC) | 36.7 (35.0–39.3) | 36.7 (35.0–40.4) | 36.7 (35.0–40.4) |
Number of patients with malaria (%) | 71 (39.6%) | 250 (44.5%) | 312 (42.1%) |
Number of male patients (%) | 93 (51.9%) | 277 (49.3%) | 370 (49.9%) |
Treatment outcomes during follow-up | |||
Number of patients with malaria (%) | 110 (61.4%) | 322 (57.3%) | 432 (58.2%) |
Time-to malaria (days) | 107 (28–149) | 90 (13–153) | 90 (13–153) |
Parasitaemia in patients with malaria (parasites μL−1) | 48,926 (64–1,496,212) | 36,081 (12–260,000) | 39,275 (12–1,496,212) |
Number of patients lost before day 90 (%) | 4 (2.19%) | 18 (3.20%) | 22 (2.95%) |
Follow-up time of lost patients (days) | 60 (60–62) | 60.5 (20–80) | 60 (20–89) |
